Login to Your Account

FDA queries Arrowhead on phase II tox in HBV; ARC-520 put on hold

By Randy Osborne
Staff Writer

Wednesday, November 9, 2016

Arrowhead Pharmaceuticals Inc. “should receive a letter from the [FDA] within 30 days that spells out what they want,” President and CEO Christopher Anzalone told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription